Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancer

CONCLUSION: The present data support MAP2 as a novel biomarker in PCA specimens. MAP2 is correlated with tumor grade and MAP2 high-expressing PCA is associated with an increased risk of biochemical recurrence after radical prostatectomy. Future studies are necessary to evaluate MAP2 as a valuable immunohistochemical biomarker in preoperative PCA diagnostic procedures, in particular with regard to treatment modalities.PMID:38310601 | PMC:PMC10838842 | DOI:10.1007/s00432-023-05579-0

Source: Clinical Prostate Cancer - February 4, 2024 Category: Cancer & Oncology Authors: Johannes Stein Eliana Krappe Anika Kremer Marcus V Cronauer Markus Essler Alexander Cox Niklas Kl ümper Philipp Krausewitz J örg Ellinger Manuel Ritter Glen Kristiansen Michael Majores Source Type: research